Promega pBIND-GR Vector

NR ligand binding domain fused to yeast GAL4 TF DBD in the FN26A (BIND) Flexi Vector or use pBIND-Er∝ and pBIND-GR Vectors. Fusion protein NR activates luc2P reporter controlled by 9X GAL4 UAS in pGL4.35. Use pGL4.36 MMTV LTR for androgen or GC responses.

Supplier:  Promega E1581

Catalog No. PRE1581

Description

• Vectors To Bind Nuclear Receptors Using Recognition Sequences or One-Hybrid Assay
• Create a binding domain fusion with the pFN26 (BIND) hRluc-neo Flexi(R) Vector and use with the pGL4.35[luc2P/9XGAL4UAS/Hygro] Vector
• Mouse mammary tumor virus long terminal repeat in pGL4.36[luc2P/MMTV/Hygro] Vector assesses androgen or glucocorticoid responses
• The estrogen receptor ligand binding domain (pBIND-Er∝) and the glucocorticoid receptor ligand binding domain (pBIND-GR) are already cloned

Specifications

• Content And Storage: -30°C to -10°C
• For Use With (Application): Discovery of Nuclear Receptor Ligands and Modulators, Drug Discovery/HTS, Cancer Research, Inflammation Research, Environmental Toxicology
• Quantity: 20 μg

By use of this product, researcher agrees to be bound by the terms of this limited use statement. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.
Researchers may use this product for research use only, no commercial use is allowed. Commercial Use means any and all uses of this product and derivatives by a party for monetary or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that Researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, Researchers must either: (1) use luminescent assay reagents purchased from Promega Corporation for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. Promega makes no representations or warranties of any kind, either expressed or implied, including for merchantability or fitness for a particular purpose with regards to the product. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA. The above license relates to Promega patents and/or patent applications on improvements to the luciferase gene.
Australian Patent 2001 285278 and other patents pending.
The CMV promoter and its use are covered under U.S. Patents 5,168,062 and 5,385,839 owned by the University of Iowa Research Foundation, Iowa City, Iowa, and licensed for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation.
Licensed from University of Georgia Research Foundation, Inc., under U.S. Patents 5,292,658; 5,418,155; Canadian Patent 2,105,984 and related patents.
Mfr. No. E1380: Patent Pending.